EMA’s mCombriax Vaccine Recommendation
EMA’s mCombriax Vaccine Recommendation Ushers in Dual Protection Era
The mCombriax vaccine recommendation from the European Medicines Agency (EMA) marks a milestone for individuals aged 50 and older. EMA has recommended marketing authorisation for mCombriax, the first messenger RNA (mRNA) vaccine targeting both COVID-19 caused by SARS-CoV-2 and seasonal influenza. This addresses the dual burden of these respiratory illnesses, which together account for substantial morbidity in Europe, including 281,728,062 reported COVID-19 cases as of 1 February 2026 and up to 50 million annual symptomatic influenza cases in the European Economic Area (EEA). Key findings highlight its non-inferior immunogenicity compared to separate approved vaccines, offering a single-shot alternative that could streamline vaccination efforts.
Proven Immune Response Edge
Clinical data from a pivotal study involving 8,000 participants aged 50 and older demonstrated that mCombriax elicited antibody levels against SARS-CoV-2 and influenza strains (A-H1N1, A-H3N2, and B Victoria lineage) statistically non-inferior to those achieved with Spikevax combined with Fluzone HD or Fluarix. Supporting evidence includes a complementary study on the influenza-only mRNA component, confirming its capacity to prevent illness and induce robust immune responses. These results highlight the vaccine’s potential to mitigate co-infection risks, which can lead to more severe outcomes than single infections, particularly in vulnerable populations. The mCombriax vaccine recommendation positions it as a viable single-dose strategy amid circulating strains aligned with 2023/2024 EMA and World Health Organization (WHO) recommendations.
Trial Backbone and Strain Matching
The mCombriax vaccine recommendation by EMA’s Committee for Medicinal Products for Human Use (CHMP) rests on immunogenicity data from randomised controlled trials, including the main study comparing mCombriax directly against established monovalent vaccines, alongside supportive evidence from an influenza-specific mRNA trial. Vaccine composition targets SARS-CoV-2 strains per EMA’s 2023/2024 guidance and WHO-recommended influenza variants, with provisions for annual updates to match community circulation. Common adverse events, such as injection site pain, fatigue, and fever—occurring in more than 1 in 10 recipients—resolve medically within 3 days, informing the safety profile evaluated by CHMP.
Boosting EU Vaccination Efficiency
Following CHMP’s positive opinion, the European Commission will finalise EU-wide marketing authorisation, after which pricing and reimbursement decisions devolve to individual Member States, considering integration into national health systems. As mCombriax expands options for vaccination campaigns targeting at-risk groups aged 50+, it potentially reduces administrative costs and improving uptake through simplified dosing amid persistent COVID-19 and influenza burdens. Its single-shot efficiency could enhance resource allocation, influence market access negotiations by demonstrating non-inferiority to comparators, and account for averted co-infection severities.
